Emgality demonstrated a consistent safety profile across five Phase 3 studies in migraine and episodic cluster headache (N=3262)1-7
The most frequent adverse reactions with Emgality in the EVOLVE-1, EVOLVE-2, and REGAIN clinical trials were injection site reactions1
The safety of Emgality was evaluated in >2500 patients with migraine across 3 clinical trials1
A pooled analysis of 3 clinical trials (EVOLVE-1, EVOLVE-2, and REGAIN) that enrolled 2886 patients showed7,11:
Hypertension rates were below 1.4% for patients on Emgality 120 mg and placebo, and constipation rates were 1.0% for patients on Emgality 120 mg vs 0.6% for patients on placebo7,11
Hypertension was reported as a likely cardiovascular treatment-emergent adverse event (TEAE) in11:
Constipation was reported as an adverse reaction in7,12:
Lilly continues to monitor the safety data of Emgality in the general population.